Skip to content

Gut Microbiome in Orthopaedics: Revision Total Knee Arthroplasty

Gut Microbiome in Orthopaedics: Investigating the Role of Gut Microbiome Composition in Total Knee Arthroplasty Failure

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06951477
Acronym
GUMBO
Enrollment
30
Registered
2025-04-30
Start date
2025-10-31
Completion date
2027-12-31
Last updated
2025-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis, Knee, Revision Total Knee Arthroplasty

Keywords

Revision TKA, Gut Microbiome, Implant Loosening, Inflammation, Weight-Bearing Computed Tomography, PET/CT

Brief summary

Many patients who receive knee replacement surgery must return for a revision (or repeat) surgery due to ongoing pain, stiffness, infection, or implant loosening. The role of the gut microbiome-the collection of bacteria and other microbes within the human gastrointestinal tract-is just beginning to be recognized in orthopaedics. The gut microbiome has been found to affect the immune response and bone regulation, potentially contributing to infection or loosening after total joint replacement. Antibiotics are regularly used in orthopaedic surgery to reduce the risk of infection, yet they might also harm gut microbiota and reduce their potentially beneficial effects. As a result, understanding the relationship between gut microbiota and surgical outcomes has become increasingly important. Therefore, this study aims to determine if there are differences in gut microbiota composition between patients with well-functioning knee replacements and those requiring revision knee replacements. Additional study aims include assessing inflammation, implant loosening, metal ion levels, and circulating bacteria in blood or tissue between well-functioning or failed knee replacements.

Interventions

PROCEDURERevision Total Knee Arthroplasty

Study participants must be scheduled to receive a revision TKA.

Sponsors

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Scheduled to undergo a revision TKA * Willing and able to comply with follow-up requirements * Ability to provide informed consent * Ability to read, write, and speak English

Exclusion criteria

* Pregnancy * Less than 3 months post-operation from primary surgery * Diagnosis of periprosthetic fracture * Scheduled for DAIR (debridement, antibiotics, and implant retention) revision surgery * Scheduled for stage 2 PJI revision

Design outcomes

Primary

MeasureTime frameDescription
Gut Microbiome CompositionGut microbiome composition will be assessed pre-operatively and at 5 days and 6 weeks post-operation to determine how it changes post-operation.The gut microbiome composition of the revision total knee arthroplasty (TKA) cohort prior to revision surgery will be compared to that of the well-functioning TKA cohort. Additionally, we will evaluate changes in the gut microbiome within the revision cohort from before surgery to six weeks after surgery.

Secondary

MeasureTime frameDescription
Inducible Displacement Measurements with Weight-Bearing Computed Tomography (WBCT)WBCT exams will be performed at one timepoint prior to the study participant's revision surgery.Seated and standing WBCT exams will be performed. The bone and implant will be segmented, and a novel software (WBCT-based radiostereometric analysis (WBCT-RSA)) will be used to measure implant motion between the double seated exams (precision) or seated and standing exams (inducible displacement). Change in implant position will be measured in millimeters as maximum total point motion (MTPM). MTPM will be compared between the revision TKA cohort and a cohort with well-functioning implants.
Inflammation in the Knee Joint Based on [18F]FEPPA Standard Uptake Values (SUV)PET/CT exams will be performed at one timepoint prior to the study participant's revision surgery.Positron Emission Tomography/Computed Tomography (PET/CT) of the knee joint will be performed using the radiotracer \[18F\]FEPPA, which binds to molecules highly expressed on inflammatory cells. Radiotracer uptake will be quantified using SUV. SUV near the bone and joint will be calculated and compared between the revision TKA cohort and the well-functioning TKA cohort.

Other

MeasureTime frameDescription
[18F]FEPPA Activity and Microbiome CompositionPET/CT exams will be performed pre-operatively and will be compared to the gut microbiome from pre-operation to 6 weeks post-operation, and to the intra-operative joint microbiome.Joint and gut microbiome composition will be compared to \[18F\]FEPPA activity, to assess whether alterations in the gut microbiome contribute to increased inflammation in the knee joint.
Inducible Displacement and Microbiome CompositionInducible displacement exams will be performed pre-operatively and will be compared to the gut microbiome from pre-operation to 6 weeks post-operation, and to the intra-operative joint microbiome.Joint and gut microbiome composition, along with inducible displacement measurements, will be assessed to determine whether alterations in the gut microbiome lead to increased within-bone implant motion.
[18F]FEPPA Activity and Metal Ion LevelsPET/CT exams will be performed pre-operatively and will be compared to the amount of circulating metal ions pre-operation.\[18F\]FEPPA activity from PET/CT will be used to detect the amount of inflammation present in the knee joint. Metal ion levels (cobalt, chromium, nickel, and titanium) will be measured pre-operatively and the relationship between inflammation and circulating metal ions will be assessed.
[18F]FEPPA Activity and Implant Wear VolumePET/CT exams will be performed pre-operatively and will be compared to the amount of wear that has occurred on implants retrieved during revision surgery.\[18F\]FEPPA activity from PET/CT will be used to detect the amount of inflammation present in the knee joint. An optical coordinate measuring machine will be used to quantitatively measure the amount of volume loss from the retrieved implant components as an indicator of wear. The relationship between volume loss and \[18F\]FEPPA activity will be assessed.
Implant Wear Volume and Within-Bone Implant Motion from Inducible Displacement ExamsInducible displacement exams will be performed pre-operatively and will be compared to the amount of wear that has occurred on implants retrieved during revision surgery.Seated and standing WBCT exams will be performed. The bone and implant will be segmented, and a novel software (WBCT-RSA) will be used to measure implant motion between the seated and standing exams (inducible displacement). Change in implant position will be measured in millimeters as MTPM. An optical coordinate measuring machine will be used to quantitatively measure the amount of volume loss from the retrieved implant components. Inducible displacement MTPM will be compared to volume loss to determine if greater within-bone implant motion may cause greater wear of the implant component resulting in more volume loss.
Metal Ion Levels and Within-Bone Implant Motion from Inducible Displacement ExamsInducible displacement exams will be performed pre-operatively and will be compared to the amount of circulating metal ions pre-operation.Seated and standing WBCT exams will be performed. The bone and implant will be segmented, and a novel software (WBCT-RSA) will be used to measure implant motion between the seated and standing exams (inducible displacement). Change in implant position will be measured in millimeters as MTPM. Metal ion levels (cobalt, chromium, nickel, and titanium) will be measured from a blood draw prior to the revision surgery. Inducible displacement MTPM and metal ion levels will be compared to determine if greater within-bone implant motion causes greater levels of circulating metal ions.

Countries

Canada

Contacts

Primary ContactBrent Lanting, MD, MSc, FRCSC
Brent.Lanting@lhsc.on.ca519-685-8500
Backup ContactLyndsay Somerville, PhD
Lyndsay.Somerville@lhsc.on.ca519-685-8500

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026